Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure

American Journal of Cardiology

Volumn 93, Issue 10, 2004, Pages 1309-1312

  Parissis, John T ^a   Adamopoulos, Stamatis ^a   Antoniades, Charalambos ^a   Kostakis, George ^a   Rigas, Antonios ^a   Kyrzopoulos, Stamos ^a   Iliodromitis, Efstathios ^a   Kremastinos, Dimitrios ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FAS ANTIGEN; FAS LIGAND; IMMUNOMODULATING AGENT; INTERLEUKIN 6; LEVOSIMENDAN; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; HEART FAILURE; HEART MUSCLE CONTRACTILE FORCE; HUMAN; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; AGED; CARDIOTONIC AGENTS; FAS LIGAND PROTEIN; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; MALE; MEMBRANE GLYCOPROTEINS; PYRIDAZINES; VENTRICULAR FUNCTION, LEFT;

EID: 2342505687     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.01.073     Document Type: Article

References (17)

1. Kivikko M., Antila S., Eha J., Lehtonen L., Pentikainen P. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol. 42:2002;43-51
2. Hasenfuss G., Pieske B., Castell M., Kretschmann B., Maier L.S., Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation. 98:1998;2141-2147
3. Follath F., Cleland J.G., Just H., Papp J.G., Scholz H., Peuhkuinen K., Harjola V.P., Mitrovic V., Abdalla M., Sandell E.P., Lehtonen L. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study a randomized double-blind trial). Lancet. 360:2002;196-202
4. Slawsky M.T., Colucci W.S., Gottlieb S.S., Greenberg B.H., Haeusslein E., Hare J., Hutchins S., Leier C.V., Lejemtel T.H., Loh E., et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation. 102:2000;2222-2227
5. Kivikko M., Lehtonen L., Colucci W.S. Sustained hemodynamic effects of intravenous levosimendan. Circulation. 107:2003;81-86
6. Gould K.L., Lipscomb K., Hamilton G.W., Kennedy J.W. Relation of left ventricular shape, function and wall stress in man. Am J Cardiol. 34:1974;627-634
7. Mann D.L., Young J.B. Basic mechanisms in congestive heart failure recognizing the role of pro-inflammatory cytokines. Chest. 105:1994;897-904
8. Adamopoulos S., Parissis J., Kremastinos D. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail. 3:2001;517-526
9. Okuyama M., Yamagouchi S., Nozaki N., Yamaoka M., Shirakabe M., Tomoike H. Serum levels of soluble form of Fas molecule in patients with congestive heart failure. Am J Cardiol. 79:1997;1698-1701
10. Yamagouchi S., Yamaoka M., Okuyama M., Nitoube J., Fukui A., Shirakabe M., Shirakawa K., Nakamura N., Tomoike H. Elevated circulating levels and cardiac secretion of soluble Fas Ligand in patients with congestive heart failure. Am J Cardiol. 83:1999;1500-1503
11. Finkel M.S., Oddis C.V., Jacob T.D., Watkins S.C., Hattler B.G., Simmons R.L. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 257:1992;387-389
12. Sasayama S., Matsumori A., Kihara Y. New insights into the pathophysiological role for cytokines in heart failure. Cardiovasc Res. 42:1999;557-564
13. Behrends M., Peters J. The calcium sensitizer levosimendan attenuates endotoxin-evoked myocardial dysfunction in isolated guinea pig hearts. Intensive Care Med. 29:2003;1802-1807
14. Paulus W.J. How are cytokines activated in heart failure? Eur J Heart Fail. 1:1999;309-312
15. + channel in rat arterial myocytes. J Pharmacol Exp Ther. 283:1997;375-383
16. Milani R.V., Mehra M.R., Endres A., Eigler A., Cooper E.S., Lavie C.J. Jr, Ventura H.O. The clinical relevance of circulating tumor necrosis-alpha in acute decompensated chronic heart failure without cachexia. Chest. 110:1996;992-995
17. Parissis J., Venetsanou K., Mentzikof D., Ziras N., Kefalas C., Karas S. Tumor necrosis factor-α serum activity during treatment of acute decompensation of cachectic and non-cachectic patients with advanced congestive heart failure. Scand Cardiovasc J. 33:1999;344-350